CPL - Chalmers Publication Library
| Utbildning | Forskning | Styrkeområden | Om Chalmers | In English In English Ej inloggad.

Two novel fusion inhibitors of human respiratory syncytial virus

Anna Lundin ; Tomas Bergström ; Loubna Bendrioua ; Nina Kann (Institutionen för kemi- och bioteknik, Organisk kemi) ; Beata Adamiak ; Edward Trybala
Antiviral Research (0166-3542). Vol. 88 (2010), 3, p. 317-324.
[Artikel, refereegranskad vetenskaplig]

To search for novel drugs against human respiratory syncytial virus (RSV), we have screened a diversity collection of 16,671 compounds for anti-RSV activity in cultures of HEp-2 cells. Two of the hit compounds, i.e., the N-(2-hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide (designated as P13) and the 1,4-bis(3-methyl-4-pyridinyl)-1,4-diazepane (designated as C15), reduced the virus infectivity with IC₅₀ values of 0.11 and 0.13μM respectively. The concentration of P13 and C15 that reduced the viability of HEp-2 cells by 50% was 310 and 75μM respectively. Both P13 and C15 exhibited no direct virucidal activity or inhibitory effects on the virus attachment to cells. However, to inhibit formation of RSV-induced syncytial plaques P13 and C15 had to be present during the virus entry into the cells and the cell-to-cell transmission of the virus. The RSV multiplication in HEp-2 cells in the presence of P13 or C15 resulted in rapid selection of viral variants that were ∼1000 times less sensitive to these drugs than original virus. Sequencing of resistant viruses revealed presence of amino acid substitutions in the F protein of RSV, i.e., the D489G for C15-selected, and the T400I and N197T (some clones) for the P13-selected virus variants. In conclusion, we have identified two novel fusion inhibitors of RSV, and the detailed understanding of their mode of antiviral activity including selection for the drug resistant viral variants may help to develop selective and efficient anti-RSV drugs.

Nyckelord: respiratory syncytial virus, antiviral drugs, cell culture, antiviral screening, virus fusion inhibitor, drug resistence

Denna post skapades 2010-12-13. Senast ändrad 2013-07-11.
CPL Pubid: 130707


Läs direkt!

Länk till annan sajt (kan kräva inloggning)

Institutioner (Chalmers)

Institutionen för biomedicin, avdelningen för infektionssjukdomar (GU)
Institutionen för kemi- och bioteknik, Organisk kemi (2006-2014)


Farmaceutisk mikrobiologi

Chalmers infrastruktur